Already on the market with a topical formulation of lotilaner for Demodex blepharitis, Xdemvy, Tarsus Pharmaceuticals Inc. is now pursuing a “pipeline-in-a-pill” strategy and developing the one-time veterinary antiparasitic agent in various formulations for Lyme disease, rosacea and meibomian gland dysfunction. On 22 February, the Irvine, CA-based company unveiled Phase IIa data showing strong tick-killing capability in human volunteers that it believes could position lotilaner as an on-demand prophylaxis for people at moderate-to-high risk for contracting Lyme disease.
Tarsus Demonstrates Lotilaner’s Potential In Preventing Lyme Disease
Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.
More from Clinical Trials
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.